Please assess the completion status of the following clinical trial:

Trial Title: Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected adults, who were receiving antiretroviral therapy including efavirenz for at least 6 months~* plasma HIV RNA\<400 cp/ml during the previous 4 months on 2 occasions 14 days apart~* Severe dyslipidemia with Low-Density Lipoprotein cholesterol (LDL-c) \>3.4 mmol/L in the presence of at least one of the 3 following coronary heart disease (CHD) risk factors: age\>45 among males or age\>55 among females, hypertension, current smoking, family history of CHD~* Low-Density Lipoprotein cholesterol (LDL-c)\>4.1 mmol/L regardless of CHD risk factors.~Exclusion Criteria:~* Protease inhibitors use within the previous 6 months,~* Prior exposure to nevirapine~* Asparate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5N if hepatitis virus B or C were negative~* AST or ALT\>1.25N if hepatitis virus B or C were positive~* Fasting glycemia\>1.26g/L,~* Current CHD~* Triglycerides\>4.6 mmol/L~* Introduction of lipid lowering drugs, corticoïds, retinoïds and betablockers within the previous 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).